Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00265616 · ClinicalTrials.gov registry record · Phase 3
Treatment of Refractory Status Epilepticus
A Phase 3 study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- Phase 3
- Development phase
- 23
- Enrollment target
NCT00265616: Clinical Trial Phase 3 study, sponsored by Brigham and Women's Hospital.
NCT00265616 is a Phase 3 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 23 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00265616, a Phase 3 study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether propofol or barbiturates should be preferred in the treatment of status epilepticus (continuous seizure activity) refractory to 2 standard antiepileptic agents.
Primary Outcome
Control of status epilepticus refractory to benzodiazepines and a first antiepileptic drug after administration of the study drug; dichotomous assessment (yes/no)
Interventions
- DRUG propofol
- DRUG thiopental/pentobarbital
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2006-05 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
Why NCT00265616 stopped before completion
NCT00265616 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which propofol is the first listed.
NCT00265616 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00265616 about?
NCT00265616 is a clinical study titled "Treatment of Refractory Status Epilepticus". The purpose of this study is to determine whether propofol or barbiturates should be preferred in the treatment of status epilepticus (continuous seizure activity) refractory to 2 standard antiepileptic agents.
What is the current status of trial NCT00265616?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 23 participants. The study started on 2006-05. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00265616?
The interventions under investigation include: propofol (DRUG), thiopental/pentobarbital (DRUG).
Who is sponsoring clinical trial NCT00265616?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00265616's enrollment target sits among peer trials
23 1952nd of 2000 higher than 48 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia